Clinical trial
VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory…
NCT00085696 · Millennium Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00085696 |
|---|---|
| Title | VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma |
| Official title | A Phase 2 Study of VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma |
| Lead sponsor | Millennium Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | B-Cell Lymphoma, Follicular Lymphoma, Marginal Lymphoma |
| Intervention type | Drug |
| Interventions | VELCADE and rituximab |
| Enrollment | 66 |
| Start date | May 1, 2004 |
| Primary completion | Apr 1, 2006 |
| First posted | Jun 15, 2004 |
| Last update posted | Feb 11, 2008 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: